<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Sylvain LECOMTE &#8211; Theradiag</title>
	<atom:link href="https://www.theradiag.com/en/author/slecomte/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.theradiag.com</link>
	<description>INNOVATION FOR BIOTHERAPIES</description>
	<lastBuildDate>Tue, 29 Mar 2022 12:54:29 +0000</lastBuildDate>
	<language>en-GB</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.8.12</generator>

<image>
	<url>https://www.theradiag.com/wp-content/uploads/2019/09/cropped-icone-bulle-theradiag-2-32x32.png</url>
	<title>Sylvain LECOMTE &#8211; Theradiag</title>
	<link>https://www.theradiag.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>30/03/2022 Evolution of governance</title>
		<link>https://www.theradiag.com/en/30-03-2022-evolution-of-governance/</link>
		
		<dc:creator><![CDATA[Sylvain LECOMTE]]></dc:creator>
		<pubDate>Wed, 30 Mar 2022 05:30:14 +0000</pubDate>
				<category><![CDATA[Press Releases]]></category>
		<guid isPermaLink="false">https://www.theradiag.com/?p=18861</guid>

					<description><![CDATA[ ]]></description>
		
		
		
			</item>
		<item>
		<title>Presentation of the 2021 full year results (only available in french) – 2022, 21st  March</title>
		<link>https://www.theradiag.com/en/presentation-of-the-2021-full-year-results-only-available-in-french-2022-21st-march/</link>
		
		<dc:creator><![CDATA[Sylvain LECOMTE]]></dc:creator>
		<pubDate>Mon, 21 Mar 2022 19:29:36 +0000</pubDate>
				<category><![CDATA[Financial presentations]]></category>
		<guid isPermaLink="false">https://www.theradiag.com/?p=18845</guid>

					<description><![CDATA[]]></description>
		
		
		
			</item>
		<item>
		<title>24/09/2020: Theradiag opens a new site in Tours</title>
		<link>https://www.theradiag.com/en/24-09-2020-theradiag-opens-a-new-site-in-tours/</link>
		
		<dc:creator><![CDATA[Sylvain LECOMTE]]></dc:creator>
		<pubDate>Thu, 24 Sep 2020 06:00:41 +0000</pubDate>
				<category><![CDATA[Press Releases]]></category>
		<guid isPermaLink="false">https://www.theradiag.com/?p=16668</guid>

					<description><![CDATA[Croissy-Beaubourg, September 24, 2020, 8:00am CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER, eligible for the French PEA-PME personal equity plan), a company specializing in in vitro diagnostics and theranostics, has opened a new site in Tours, France. &#160; In July, Theradiag announced a partnership with the University of Tours: an exclusive licensing contract for making [&#8230;]]]></description>
		
		
		
			</item>
		<item>
		<title>21/07/2020 : Theradiag announces its revenue for the first half of 2020</title>
		<link>https://www.theradiag.com/en/21-07-2020-theradiag-announces-its-revenue-for-the-first-half-of-2020/</link>
		
		<dc:creator><![CDATA[Sylvain LECOMTE]]></dc:creator>
		<pubDate>Tue, 21 Jul 2020 15:45:00 +0000</pubDate>
				<category><![CDATA[Press Releases]]></category>
		<guid isPermaLink="false">https://www.theradiag.com/?p=16476</guid>

					<description><![CDATA[H1 2020 revenue up 16.5 % for Theranostics Theranostics performed well in all regions Cash position at June 30, 2020 in line with the budget: €1.7 million Croissy-Beaubourg, July 21, 2020, 5.45 pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and Theranostics, today announces its consolidated half-year revenue [&#8230;]]]></description>
		
		
		
			</item>
		<item>
		<title>01/07/2020 : The University of Tours and Theradiag sign two agreements simultaneously: an exclusive licensing agreement for the production of COVID-19 viral proteins and a global collaboration agreement that could lead to the creation of further partnerships</title>
		<link>https://www.theradiag.com/en/01-07-2020-the-university-of-tours-and-theradiag-sign-two-agreements-simultaneously-an-exclusive-licensing-agreement-for-the-production-of-covid-19-viral-proteins-and-a-global-collaboration-agreeme/</link>
		
		<dc:creator><![CDATA[Sylvain LECOMTE]]></dc:creator>
		<pubDate>Wed, 01 Jul 2020 15:45:00 +0000</pubDate>
				<category><![CDATA[Press Releases]]></category>
		<guid isPermaLink="false">https://www.theradiag.com/?p=16398</guid>

					<description><![CDATA[Croissy-Beaubourg, July, 1, 2020, 5:45 pm CEST – The University of Tours and THERADIAG (ISIN: FR0004197747, Ticker: ALTER, eligible for the French PEA-PME personal equity plan), a company specializing in in vitro diagnostics and theranostics, have just signed two agreements simultaneously. The first is an exclusive licensing agreement for the production and access to viral [&#8230;]]]></description>
		
		
		
			</item>
		<item>
		<title>Financial Presentation : Investir Day October 2019</title>
		<link>https://www.theradiag.com/en/financial-presentation-investir-days-october-2019/</link>
		
		<dc:creator><![CDATA[Sylvain LECOMTE]]></dc:creator>
		<pubDate>Thu, 28 Nov 2019 18:00:14 +0000</pubDate>
				<category><![CDATA[Financial presentations]]></category>
		<category><![CDATA[Latest Financial Presentations]]></category>
		<guid isPermaLink="false">https://www.theradiag.com/?p=13041</guid>

					<description><![CDATA[You will find here our communication during Investir Day Congress of october 2019. (Document in French)]]></description>
		
		
		
			</item>
		<item>
		<title>18/11/2019 : THERADIAG announces CE marking approval  for its new i-Track10 automated analyzer for biotherapy monitoring</title>
		<link>https://www.theradiag.com/en/theradiag-announces-ce-marking-approval-for-its-new-i-track10-automated-analyzer-for-biotherapy-monitoring/</link>
		
		<dc:creator><![CDATA[Sylvain LECOMTE]]></dc:creator>
		<pubDate>Mon, 18 Nov 2019 07:00:00 +0000</pubDate>
				<category><![CDATA[Press Releases]]></category>
		<guid isPermaLink="false">https://www.theradiag.com/?p=12706</guid>

					<description><![CDATA[Télécharger/Download Croissy-Beaubourg, November 18, 2019, 8:00 am CET – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, today announces that it has obtained the CE marking for its i-Track10 automated analyzer for biotherapy monitoring. One of the key points of the agreement signed last April with IDS, which manufactures [&#8230;]]]></description>
		
		
		
			</item>
	</channel>
</rss>
